Clinical spectrum and genetic variation of six patients with methylmalonic aciduria (MMA); a report from Iran Authors: Zahra Beyzaei, Hossein Moravej, Mohammad Hadi Imanieh, Sorour Inaloo, Bita Geramizadeh Published: 2024 ABSTRACT AbstractObjectiveMethylmalonic acidemia (MMAs) is known as a severe, complex, and lethal disorder of methylmalonate and cobalamin. The patients with MMA may have developmental, neurological, and metabolic disorders such as liver disease. Here, we aim to evaluate 6 Iranian patients suspected to MMA disorder.Study designWe will provide genetic results, biochemical analysis and treatment for these patients. Liquid chromatography-tandem mass spectrometry (LC–MS/MS) and variant screening in probands by whole exome sequencing (WES) were performed.ResultsA total of six homozygous variants were identified, including five previously identified variants and one novel variant, in the two MMA-causing genes as follows: c.577G > C, c.290 + 69G > T, c.662T > A, c.290 + 69G > T of MMAB, and c.100dupA, c.394 C > T of MMACHC. Sanger sequencing confirmed the identified variants. Additionally, metabolomics data analysis reliably identified elevated C3 and MMA levels, as well as abnormalities in the amino acid profile, indicating the presence of pathogenic variants.ConclusionsOur findings expand the global spectrum of genotypes in MMA. While WES, combined with metabolomics and biochemical analysis, offers valuable insights for accurate diagnosis and subtyping of MMA, it is most beneficial in complex cases where clinical findings are unclear.Keywords: Methylmalonic acidemia, Vitamin B12/hydroxocobalamin, Novel mutation, Whole exome sequencing Background Methylmalonic acidemia (MMA) is a rare group of autosomal recessive inborn errors of metabolism that result in multisystem disease [1]. The overall incidence of MMA varies based on the subtype and ethnicity; however, it is estimated to be approximately 1 in 48,000 to 90,000 people [2]. MMA is a genetically heterogeneous disorder with three main subtypes: Methylmalonic acidemia (AdoCbl deficiency), Combined methylmalonic acidemia and homocystinuria (AdoCbl and MeCbl deficiency), and Homocystinuria (MeCbl deficiency). Various subtypes of isolated methylmalonic acidemia (MMA) can arise from pathogenic variants in the MMUT, MMAA, MMAB, MMADHC, and MCEE genes [3]. Additionally, the presence of MMA with homocystinuria can be confirmed in genes such as MMACHC (cblC), MMADHC (cblD-combined and cblD-homocystinuria), MTRR (cblE), LMBRD1 (cblF), MTR (cblG), ABCD4 (cblJ), THAP11 (cblX-like), ZNF143 (cblX-like), or through a hemizygous variant in HCFC1 (cblX) [4]. Deficiency in methylmalonyl-CoA mutase (MCM) or in the synthesis of its active cofactor, adenosylcobalamin (AdoCbl), leads to the accumulation of high levels of methylmalonic acid [5, 6]. The diagnosis of symptomatic MMA patients is based on clinical, biochemical, and molecular genetic data. The gold standard for initial diagnosis and ongoing management after an abnormal acylcarnitine profile is biochemical testing using urine organic acids, as well as the measurement of plasma amino acids and total plasma homocysteine. However, mutation analysis helps to decide the right treatment strategy for patients, especially for asymptomatic MMA patients. In the majority (> 97%) of patients with MMA, the disease is caused by pathogenic variants in the MMAA, and MMAB, while a variant in other genes only accounts for 1–3% of patients [7, 8]. To date, more than 300 different variants have been reported in different subtypes, most of which are missense or nonsense variants [9, 10]. Without immediate diagnosis and appropriate management, MMA patients become progressively encephalopathic and ultimately progress to coma and even death [11, 12]. Whole exome sequencing (WES) is utilized for the detection and classification of heterogeneous disorders such as MMA. The ability to prompt detection of genes and cost-effectiveness are the two most important advantages of using WES in the diagnosis of MMA. In the present study, we aimed to identify the genetic background of 6 Iranian suspected MMA patients using WES. Materials and methods Patients From May 2020 to November 2022, we retrospectively recruited a total of six patients (3 males, 3 females) and their families suspected of MMA based on clinical manifestations and biochemical results at Shiraz Transplant Research Center (STRC) and the database registry of Metabolic (no. 1400–7860), Shiraz University of Medical Sciences. Clinical manifestations of patients included poor feeding, lethargy, failure to thrive, vomiting, hypotonia, and intellectual disability, which persisted even after the initiation of medication. Therefore, they were referred to us for molecular analysis. The Ethics Committee of Shiraz University of Medical Sciences also approved this study (Approval #: IR.SUMS.REC.1402.202), which was following the Declaration of Helsinki. Written informed consent was obtained from all their parents in this study because the patients were younger than 18 years old. Screening for inherited metabolic disorders Plasma amino acid profile, plasma acylcarnitine profile, plasma methylmalonic acid, and free carnitine were measured by using liquid chromatography-tandem mass spectrometry (LC–MS/MS) (AB Sciex 2200, USA). The reference levels of propionyl carnitine (C3) in the plasma were < 1.25 µmol/L. A semi-quantitative colorimetric test was performed to detect urine ketones. The blood ketone test was not performed. Chromatographic separation was achieved on a C18 column (length 125 mm, internal diameter 3.0 mm, particle size 3.5 μm; Agilent) at a column temperature of 49 °C. Eluent A consisted of 0.1% formic acid, and 2.5 mM ammonium acetate, in water. Eluent B consisted of 0.1% formic acid, and 2.5 mM ammonium acetate, in acetonitrile. The gradient elution process followed this program: starting with 100% A at a flow rate of 0.5 ml/min for 0.5 min, followed by a gradual decrease to 60% A at the same flow rate over 3 min, then holding steady for 4 min, further decreasing to 40% A at the same flow rate over 3.5 min, and finally decreasing to 5% A over 1 min at the same flow rate. Afterward, re-equilibration was carried out at 100% A with a flow rate of 0.5 ml/min for 5 min. The total duration of the program was 24 min. Analytes were quantified using scheduled multiple reaction monitoring (MRM) with a total scan time of 0.5 s and a scan time window of 0.5 min. The quadrupoles were operating at unit resolution. Calibration was established by spiking plasma samples with varying amounts of acylcarnitine standards. A ten-point calibration was executed by adding incremental quantities of each standard and IS. Subsequently, calibration curves were formulated and adjusted using linear regression without any weighting. The data analysis was conducted using Analyst 1.5® software by AB Sciex. Next generation sequencing and sanger sequencing Mutation screening was performed by whole exome sequencing (WES) for the probands by Illumina Hiseq 4000 platform with 100X depth of coverage and 101 bp paired-end reads. Raw sequence data analysis including base calling, de-multiplexing, aliment to the hg19 human reference genome, and variant calling was performed. Scale-Invariant Feature Transform (SIFT), Polymorphism Phenotyping v2 (PolyPhen2), and MutationTaster were further employed for in silico analysis. The population frequency of each variation was correspondingly estimated using the data from the Genome Aggregation Database (gnomAD) and Iranome database. The HGMD database, the ClinVar database, and the literature were utilized to determine whether the mutations had been previously reported. For variant interpretations, the American College of Medical Genetics and Genomics (ACMG) guidelines were used, and the sequence variants were described according to the Human Genome Variation Society Nomenclature [13, 14]. Finally, Sanger sequencing confirmed candidate variants in the parents in each family. Primers for polymerase chain reaction were designed by Oligo 7 software. DNA sequencing was performed using an ABI 3500 Genetic Analyzer (Applied Biosystems, USA). Treatment and follow-up Nutrition metabolic therapy, including low protein diet with limited amounts of isoleucine, valine, threonine, and methionine, a high-calorie diet, betaine powder, L-carnitine tablet (50–100 mg/kg/day), oral cyanocobalamin, and if necessary, intramuscular cobalamin (hydroxy cobalamin) were provided to patients. Hydroxocobalamin was injected once every 7–10 days, 1 mg each time for patients who were not responsive to oral cyanocobalamin. The follow-up period lasted for 2 years, during which serum methylmalonic acid, homocysteine, vitamin B12, L-carnitine, ammonia, liver function tests (LFTs), and complete blood count (CBC) were checked every 6 months. Results Clinical manifestation Of six patients, four presented with the early-onset form of the condition (< 1 year old); while the remaining two patients had the late-onset form (> 1 year old). The mean age of the probands was 6.2 years old and the average delay to accurately confirm genetic diagnosis was 3.1 years (range: 0.6-8 years). Among the six cases in our study, two patients (P1 and P3) exhibited an acute onset of symptoms, which were non-specific at first, including feeding problems, diarrhea, vomiting, and lethargy, starting at one month of age. Both were diagnosed through newborn screening, and after confirmation by additional tests, they received treatment with cobalamin (B12) supplementation, a low-protein diet, and L-carnitine. Their symptoms gradually improved within two weeks after initiating symptomatic treatment. The remaining four patients (P2, P4, P5, P6) exhibited a progressive course, characterized by intellectual impairment and developmental delays. They had a Developmental quotient (DQ) test of 70 or less. Metabolic acidosis was observed in these cases when the patients were older than one year. All of these patients exhibited symptoms such as feeding difficulties, short stature, poor weight gain, hyperglycemia, ketosis, and metabolic acidosis over several months. Additionally, growth parameters (height/length, weight, and head circumference) were consistently below the normal range for their ages. Notably, P4 was unable to walk or speak until 25 months of age, and P2 did not walk until 18 months of age (Table 1). Table 1Clinical characteristics, diagnosis, treatment, and prognosis of MMA patients in this studyCase no./GenderOnset (month)Current age (year)First Clinical indicationOn presentationAfter treatment (L-carnitine, hydroxyl cobalamin (B12), betaine)Liver Function test (LFT)Renal Function TestComplete blood count (CBC)Blood gasBlood C3Serum MMAPlasma Amino acid profileAmmonia levelKetone in urinetHcyBlood C3Serum MMAPlasma Amino acid profileAmmonia levelKetone in urinetHcyP1/M52.5Vomiting, acute disease onsetAST: 21 U/LALT: 40 U/LBilirubin (Total): 0.6 mg/dLALP: 89 u/lAlbumin: 4.0 g/dLPT: 13 sLDH: 250 U/LSerum Creatinine: 0.8BUN: 15.5 mg/dLK+: 3.9PO4²⁻: 5.4Ca2+:9.05Na+: 132-WBC: 3.2 × 10³/µL-Hemoglobin: 10.5 g/dL-Hematocrit: 32.5%-Platelet Count: 100 × 10³/µL-Differential: Neutrophils 42%, Lymphocytes 48%, Monocytes 8%, Eosinophils 2%pH = 7.20,pCO2 = 14 mmHg,HCO3⁻ = 8 mEq/L,Anion Gap = 26 mEq/L,12.1150,000Abnormal (high Ser, Gly, Ala, Tyr, Trp, Lys; low Thr, Val, Ile, Met)136Positive125.48.7223,000Normal-Negative21.2P2/F87Developmental delayAST: 61 U/LALT: 48 U/LBilirubin (Total): 1.4 mg/dLALP: 829 u/lAlbumin: 5.0 g/dLPT: 11.9 sLDH: 675 U/LSerum Creatinine: 0.6BUN: 8 mg/dLK+: 4.8PO4²⁻:5.5Ca2+:8.8Na+:125-WBC: 4.8 × 10³/µL-Hemoglobin: 11.2 g/dL-Hematocrit: 33.0%-Platelet Count: 80 × 10³/µL-Differential: Neutrophils 50%, Lymphocytes 40%, Monocytes 8%, Eosinophils 2%pH = 7.44, pCO2 = 32.5 mmHg, HCO3⁻ = 8.2 mEq/L, Anion Gap = 24 mEq/L,11.1945,000Abnormal (high Ser, Gly, Ala, Tyr, Trp, Lys; low Thr, Val, Ile, Met)89.7Positive146.52.74571,300Normal63Negative31P3/F41.5lethargy, acute disease onsetAST: 110 U/LALT: 78 U/LBilirubin (Total): 2.5 mg/dLALP: 735 u/lAlbumin: 4.3 g/dLPT: 13.5 sLDH: 500 U/LSerum Creatinine: 0.51BUN: 27.2 mg/dLK+: 5.6PO4²⁻: 6.2Ca2+:10.1Na+: 135-WBC: 2.5 × 10³/µL-Hemoglobin: 9.8 g/dL-Hematocrit: 30.0%-Platelet Count: 120 × 10³/µL-Differential: Neutrophils 38%, Lymphocytes 52%, Monocytes 8%, Eosinophils 2%pH = 7.27, pCO2 = 18 mmHg, HCO3⁻ = 8.4 mEq/L, Anion Gap = 26 mEq/L,18.09198,000Abnormal (high Ser, Gly, Ala, Tyr, Trp, Lys; low Thr, Val, Ile)-Positive43.51.78145,000Normal-Negative14.8P4/M1210intellectual impairment progressively and developmental delayAST: 98 U/LALT: 64 U/LBilirubin (Total): 0.5 mg/dLALP: 719 u/lAlbumin: 2.6 g/dLPT: 12.5 sLDH: 612 U/LSerum Creatinine: 1.1BUN: 31.5 mg/dLK+: 7.5PO4²⁻: 4.1Ca2+:10.6Na+: 140-WBC: 3.6 × 10³/µL-Hemoglobin: 10.0 g/dL-Hematocrit: 31.0%-Platelet Count: 110 × 10³/µL-Differential: Neutrophils 45%, Lymphocytes 45%, Monocytes 8%, Eosinophils 2%pH = 7.31, pCO2 = 23.5 mmHg, HCO3⁻ = 8 mEq/L, Anion Gap = 26 mEq/L,26.88228,600Abnormal (high Gly, hydroxypro; low Ile, Leu)149Positive43.69.75-Normal124Negative27P5/F136developmental delayAST: 26 U/LALT: 15 U/LBilirubin (Total): 0.6 mg/dLALP: 170 u/lAlbumin: 3.4 g/dLPT: 17.2 sLDH: 250 U/LSerum Creatinine: 1.5BUN: 38 mg/dLK+: 5.4PO4²⁻: 4.1Ca2+: 18.5Na+: 157-WBC: 3.5 × 10³/µL-Hemoglobin: 9.0 g/dL-Hematocrit: 32.0%-Platelet Count: 100 × 10³/µL-Differential: Neutrophils 45%, Lymphocytes 45%, Monocytes 8%, Eosinophils 2%pH = 7.42, pCO2 = 28.9 mmHg, HCO3⁻ = 8 mEq/L, Anion Gap = 25 mEq/L, Base Excess = -12 mEq/L11.3Abnormal (low leu and Ile)116Positive45.96.16-Abnormal (low leu and Ile)37Negative13.8P6/M75intellectual impairment progressivelyAST: 119 U/LALT: 68 U/LBilirubin (Total): 0.7 mg/dLALP: 255 u/lAlbumin: 2.9 g/dLPT: 10.0 sLDH: 625 U/LSerum Creatinine: 0.67BUN: 14 mg/dLK+: 4.4PO4²⁻: 5.2Ca2+: 10.4Na+: 148-WBC: 2.0 × 10³/µL-Hemoglobin: 9.8 g/dL-Hematocrit: 32.0%-Platelet Count: 130 × 10³/µL-Differential: Neutrophils 44%, Lymphocytes 46%, Monocytes 8%, Eosinophils 2%pH = 7.15, pCO2 = 39.5 mmHg, HCO3⁻ = 6 mEq/L, Anion Gap = 30 mEq/L,13.7182,000Abnormal (low leu and Ile)37Positive66.93.7231,160Abnormal (low leu and Ile)32Negative4.7WBC: normal range: 4.0–11.0 × 10³/µL; Hemoglobin: normal range: 11.0–14.0 g/dL; Hematocrit: normal range: 36.0–44.0%; Platelet Count: normal range: 150–400 × 10³/µL; ALT: normal range 7–56 U/L; AST: normal range 10–40 U/L; Bilirubin (Total): normal range 0.1–1.2 mg/dL; Alkaline Phosphatase: normal range 44–121 U/L; Albumin: normal range 3.5–5.0 g/dL; Prothrombin Time (PT): normal range 11–14 s; LDH: normal range 140–280 U/L; Serum Creatinine: 0.6–1.2 mg/dL; BUN: 7–20 mg/dL; eGFR > 60 mL/min/BSA; Potassium (K+):3.5–5.0 mmol/L; Calcium (Ca2+):8.5–10.2 mg/dL; Sodium (Na+): 135–145 mmol/L; C3: normal: 0.3–4.95 µmol/L; Serum MMA: normal < 400 nmol/L; Ammonia: normal 19–82 µmol/L; Total Homocysteine (tHcy): normal < 10 µmol/L Clinical characteristics, diagnosis, treatment, and prognosis of MMA patients in this study AST: 21 U/L ALT: 40 U/L Bilirubin (Total): 0.6 mg/dL ALP: 89 u/l Albumin: 4.0 g/dL PT: 13 s LDH: 250 U/L Serum Creatinine: 0.8 BUN: 15.5 mg/dL K+: 3.9 PO4²⁻: 5.4 Ca2+:9.05 Na+: 132 -WBC: 3.2 × 10³/µL -Hemoglobin: 10.5 g/dL -Hematocrit: 32.5% -Platelet Count: 100 × 10³/µL -Differential: Neutrophils 42%, Lymphocytes 48%, Monocytes 8%, Eosinophils 2% pH = 7.20, pCO2 = 14 mmHg, HCO3⁻ = 8 mEq/L, Anion Gap = 26 mEq/L, AST: 61 U/L ALT: 48 U/L Bilirubin (Total): 1.4 mg/dL ALP: 829 u/l Albumin: 5.0 g/dL PT: 11.9 s LDH: 675 U/L Serum Creatinine: 0.6 BUN: 8 mg/dL K+: 4.8 PO4²⁻:5.5 Ca2+:8.8 Na+:125 -WBC: 4.8 × 10³/µL -Hemoglobin: 11.2 g/dL -Hematocrit: 33.0% -Platelet Count: 80 × 10³/µL -Differential: Neutrophils 50%, Lymphocytes 40%, Monocytes 8%, Eosinophils 2% AST: 110 U/L ALT: 78 U/L Bilirubin (Total): 2.5 mg/dL ALP: 735 u/l Albumin: 4.3 g/dL PT: 13.5 s LDH: 500 U/L Serum Creatinine: 0.51 BUN: 27.2 mg/dL K+: 5.6 PO4²⁻: 6.2 Ca2+:10.1 Na+: 135 -WBC: 2.5 × 10³/µL -Hemoglobin: 9.8 g/dL -Hematocrit: 30.0% -Platelet Count: 120 × 10³/µL -Differential: Neutrophils 38%, Lymphocytes 52%, Monocytes 8%, Eosinophils 2% AST: 98 U/L ALT: 64 U/L Bilirubin (Total): 0.5 mg/dL ALP: 719 u/l Albumin: 2.6 g/dL PT: 12.5 s LDH: 612 U/L Serum Creatinine: 1.1 BUN: 31.5 mg/dL K+: 7.5 PO4²⁻: 4.1 Ca2+:10.6 Na+: 140 -WBC: 3.6 × 10³/µL -Hemoglobin: 10.0 g/dL -Hematocrit: 31.0% -Platelet Count: 110 × 10³/µL -Differential: Neutrophils 45%, Lymphocytes 45%, Monocytes 8%, Eosinophils 2% AST: 26 U/L ALT: 15 U/L Bilirubin (Total): 0.6 mg/dL ALP: 170 u/l Albumin: 3.4 g/dL PT: 17.2 s LDH: 250 U/L Serum Creatinine: 1.5 BUN: 38 mg/dL K+: 5.4 PO4²⁻: 4.1 Ca2+: 18.5 Na+: 157 -WBC: 3.5 × 10³/µL -Hemoglobin: 9.0 g/dL -Hematocrit: 32.0% -Platelet Count: 100 × 10³/µL -Differential: Neutrophils 45%, Lymphocytes 45%, Monocytes 8%, Eosinophils 2% AST: 119 U/L ALT: 68 U/L Bilirubin (Total): 0.7 mg/dL ALP: 255 u/l Albumin: 2.9 g/dL PT: 10.0 s LDH: 625 U/L Serum Creatinine: 0.67 BUN: 14 mg/dL K+: 4.4 PO4²⁻: 5.2 Ca2+: 10.4 Na+: 148 -WBC: 2.0 × 10³/µL -Hemoglobin: 9.8 g/dL -Hematocrit: 32.0% -Platelet Count: 130 × 10³/µL -Differential: Neutrophils 44%, Lymphocytes 46%, Monocytes 8%, Eosinophils 2% WBC: normal range: 4.0–11.0 × 10³/µL; Hemoglobin: normal range: 11.0–14.0 g/dL; Hematocrit: normal range: 36.0–44.0%; Platelet Count: normal range: 150–400 × 10³/µL; ALT: normal range 7–56 U/L; AST: normal range 10–40 U/L; Bilirubin (Total): normal range 0.1–1.2 mg/dL; Alkaline Phosphatase: normal range 44–121 U/L; Albumin: normal range 3.5–5.0 g/dL; Prothrombin Time (PT): normal range 11–14 s; LDH: normal range 140–280 U/L; Serum Creatinine: 0.6–1.2 mg/dL; BUN: 7–20 mg/dL; eGFR > 60 mL/min/BSA; Potassium (K+):3.5–5.0 mmol/L; Calcium (Ca2+):8.5–10.2 mg/dL; Sodium (Na+): 135–145 mmol/L; C3: normal: 0.3–4.95 µmol/L; Serum MMA: normal < 400 nmol/L; Ammonia: normal 19–82 µmol/L; Total Homocysteine (tHcy): normal < 10 µmol/L Genomic diagnostic results WES analysis revealed four cases with isolated MMA and two MMA with homocystinuria. Overall, six homozygote variants were detected in the MMA-associated genes; one of them had not been previously reported in HGMD and ClinVar databases. The novel variant included an intronic variant c.290 + 69G > T (p.?) in MMAB. In our bioinformatics analysis, we utilized PolyPhen2 and PROVEAN tools to assess the potential functional impact of a novel variant. Following the ACMG guidelines and analysis with InterVar software, this variant was classified as “Likely Pathogenic”. In addition, Sanger sequencing analysis revealed a heterozygous state in the parents. It should be mentioned that both parents were asymptomatic (Fig. 1A, B). This variant has never been reported in HGMD database, ClinVar database, or gnomAD database so far. (A) Patient’s family’s pedigree of novel variant. Black arrow shows the proband. The homozygote variant found in this patient was vertically transmitted from his father and mother respectively; (B) Validation by Sanger sequencing of MMAB gene in this family Besides, there were five previously reported variants, i.e. two missense, one split site variants in MMAB (c.577G > A; c.662T > G; c.197-1G > T), and one nonsense change (c.394 C > T), one frameshift variant (c.100dupA) in MMACHC. It is worth mentioning that all allele frequencies of the variants were searched in the Iranome database (public Iranian data set; www.iranom.ir), and none of them were reported (Fattahi et al., 2019). It should be mentioned that we have not identified any variants in other genes associated with MMA, such as those related to cobalamin metabolism defects. The diagnoses and zygosity of the six patients are shown in Table 2. Table 2The identified mutation of MMA patientsCase no.Marriage TypeGender/age at molecular diagnosis (year)GeneNucleotide changeProtein changeVariant typeZygosityACMG-AMP classificationGlobal Allele frequency (gnomAD)Local Allele frequency (Iranom)ReferencesP1Non-consanguineousM/0.6MMACHCc.100dupAp.V33fsFrameshiftHomozygousPathogenic0.0001NALerner-Ellis et al., (2006)P2consanguineousF/2.5MMACHCc.394 C > Tp.R132XNonsenseHomozygousPathogenic0.0001NALerner-Ellis et al., (2006)P3consanguineousF/0.8MMABc.577G > Ap.E193KMissenseHomozygousLikely Pathogenic0.0001NAYılmaz et alL., (2021)P4Non-consanguineousM/8MMABc.197-1G > Tp.(?)Splice siteHomozygousPathogenic0.00010.0006250Lerner-Ellis et al., (2006) P5 consanguineous F/4 MMAB c.290 + 69G > T p.(?) Intronic Homozygous Likely Pathogenic NA 0.0006250 This study P6consanguineousM/4MMABc.662T > Gp.F221CMissenseHomozygousUncertain significance0.0001NAMartín-Rivada et al., (2022)Bold type represents novel unclassified variants. NA: not reporteda The Accession Number of the relevant reference sequence(s): MMAB: RefSeq NM_052845.4; MMACHC: RefSeq NM_001330540 or NM_015506.2 The identified mutation of MMA patients Bold type represents novel unclassified variants. NA: not reported a The Accession Number of the relevant reference sequence(s): MMAB: RefSeq NM_052845.4; MMACHC: RefSeq NM_001330540 or NM_015506.2 Biochemical features of patients before and after treatment The biochemical markers consisting of the plasma C3, serum MMA, amino acid profile, ammonia level, and concentration of homocysteine were analyzed before and after treatment in all patients as presented in Table 1. Prior to initiating treatment, all patients presented with metabolic acidosis. CBC results showed that one patient (P2) had a normal white blood cell (WBC) count, while three patients (P1, P4, P5) exhibited mild neutropenia, and two patients (P3, P6) had more pronounced neutropenia. Additionally, two patients (P1, P2) had thrombocytopenia, while four patients (P3, P4, P5, P6) demonstrated mild thrombocytopenia. The vitamin B12 levels were analyzed in the serum of all patients to rule out vitamin B12 deficiency. Additionally, strikingly high levels of C3 and serum methylmalonic acid were observed in all cases. It is important to note that both P1 and P2 were diagnosed with methylmalonic acidemia with homocystinuria. Furthermore, we observed an increase in serine, glycine, alanine, tyrosine, tryptophan, and lysine, along with a decrease in threonine, valine, isoleucine, and methionine in these patients. In patients with MMA diagnosis, the plasma amino profile of P6 appeared normal. However, in P3, we observed an increase in serine, glycine, alanine, tyrosine, tryptophan, and lysine, along with a decrease in threonine, valine, and isoleucine. In P4, a high amount of glycine, hydroxyproline, and a low level of isoleucine, and leucine was seen; also, in P5 a decrease in leucine and Isoleucine was observed. The level of serum homocysteine was elevated in all patients. Liver function test (LFTs) showed elevated ALT, AST and ALP levels in patients P2, P3, P4 and P6, suggestive of mild liver damage. Total bilirubin was mildly elevated in patients P3 (2.5 mg/dL), indicating potential bilirubin metabolism dysfunction. The LFTs of the other patients were within normal limits. Regarding renal complications, only P5 developed renal issues during the follow-up period. Biochemical tests revealed elevated serum creatinine (1.5 mg/dL), BUN (38 mg/dL), and potassium (5.4 mmol/L), indicating impaired renal function. Additionally, her phosphate (4.1 mg/dL) and calcium (18.5 mg/dL) levels were abnormally high, while sodium (157 mmol/L) was elevated, suggesting significant metabolic disturbances. Oral L-carnitine, vitamin B12 (cyanocobalamin/ hydroxocobalamin), betaine powder, vitamin C, and folate were used to treat MMA. After a year of treatment, the levels of serum C3, serum MMA, and serum homocysteine were slightly decreased. The plasma amino acid profile of the two patients became normal (P3, P4). After evaluating the methylmalonic acid levels before and after vitamin B12 treatment, it was determined that P1, P3 and P6 exhibited a completely responsive type, whereas the two cases (P2, P4) demonstrated a partially responsive type. P5, on the other hand, did not respond to the treatment. Consequently, P5 was managed with a strict low valine, threonine, and isoleucine diet, along with L-carnitine supplementation. Additionally, hydroxocobalamin injections were administered once every 5–7 days, with a dosage of 1 mg each time. Following treatment, all patients experienced gradual improvements in their intelligence. Pathogenic effect of novel variant c.290 + 69G > T in MMAB We evaluate the potential pathogenicity of the variant c.290 + 69G > T (p.?) on pre-mRNA splicing, using several different freely available software including Splice Site Prediction by Neural Network (www.fruitfly.org/seq_tools/splice.html), NetGene2 (http://www.cbs.dtu.dk/services/NetGene2/), and ASSP model (wangcomputing.com/assp). The designed variant was based on MMAB gene (NM_052845.4) from NCBI. We analyzed the new splice site and its effect on splicing by comparing the difference of the splice site between the wild type and the variant. Additionally, we analyzed its pathogenicity through the WinterVar database (http://wintervar.wglab.org) in accordance with the ACMG 2015 guideline. The variant was classified as “Likely Pathogenic” with a score of " PS3-Moderate + PP4-Moderate + PP3-Supporting + PM2-Supporting”. The mutated residue may lead to protein truncation, splicing site changes or disrupt protein interaction, potentially impacting the protein’s function (Fig. 1C). Follow up In our study, the frequency of follow-up visits and biochemical parameter monitoring varied depending on each patient’s condition and the presence of complications. On average, patients were followed up every 6 months. However, for those who developed complications, follow-up visits were conducted more frequently, typically every 2 to 3 months. Regarding treatment outcomes, two patients (P4 and P6) showed satisfactory progress, with normal growth and psychomotor development following appropriate treatment. P1 and P5 exhibited developmental delays but had normal intelligence. P2 is currently leading a healthy life without symptoms. In contrast, P5 experienced significant developmental and language delays, as well as challenges with intellectual abilities due to delayed initiation of treatment. Clinically, P5 presented with recurrent metabolic crises and signs of severe metabolic acidosis during the follow-up period, which were not adequately managed due to poor adherence to the treatment regimen. Biochemically, P5 showed persistently elevated methylmalonic acid levels, a high C3/C2 ratio and renal complications, indicating poor metabolic control. Despite multiple interventions, P5’s condition worsened, and she succumbed to severe metabolic acidosis at the age of 6. Three patients (P2, P3, and P6) showed complete responsiveness to vitamin B12 treatment, as evidenced by a reduction of more than 50% in the blood C3/C2 ratio or urinary methylmalonic acid levels. The other patients (P1, P4, and P5) were classified as partially responsive to treatment. Regarding neurological signs, we observed developmental delays and intellectual impairment at disease onset. Following treatment, some neurological symptoms improved over time (more than 1-year post-treatment), although the degree of recovery varied among patients, reflecting the heterogeneity in the progression of MMA and its response to therapy. Discussion MMA is a rare inherited disease that carries a significant burden of morbidity and mortality. The mutation spectrum associated with this disorder has been extensively documented in previous literature [2, 7, 15]. However, the available data regarding overall variants from MMA patients in Iran remains limited so far [16]. Also, there is currently limited information available about the epidemiology and molecular defects in MMA patients from the Middle-East Asia region. This study provides comprehensive clinical and molecular data for a defined case group consisting of four MMAB and two MMACHC variants. We uncovered 1 novel and 5 reported variants. According to ACMG and genomics guidelines, 3 of these variants were considered pathogenic variants, 2 variants were likely pathogenic, and 1 variant was defined as a variant of uncertain significance (VUS). In the MMAB gene, one novel intronic missense variant of c.290 + 69G > T was found, which is defined as a likely pathogenic. Currently, there is limited information available regarding the potential underlying mechanism that elucidates why the newly identified variant c.290 + 69G > T (p.?) results in the pathogenic phenotype. Concerning the biochemical profile, patients harboring the c.290 + 69G > T (p.?) mutation exhibited elevated levels of blood C3, serum methylmalonic acid, and abnormal plasma amino acids, which remained abnormal both pre- and post-treatment. Timely gene sequencing is crucial for confirming the diagnosis in these cases, serving as a pivotal assessment tool. Nevertheless, the vast number of candidate variants identified within an individual’s genome presents strong obstacles when it comes to interpreting their functional implications, especially regarding variants that impact RNA splicing [17]. In non-consanguineous families, two homozygous variants were identified, suggesting the presence of compound heterozygous mutations. These families belong to a specific sub-ethnic group in Iran. The MLPA test showed no deletion in the trans allele covering the missense region. The occurrence of homozygous variants in these families may be attributed to the intermarriage within this sub-ethnic group (Lure) in Iran in previous generations. Therefore, their gene pool exhibits significant closeness and relatedness. This close genetic relationship is likely a contributing factor to the presence of homozygous variants among these patients. Sub-typing of MMA patients is an important step in individualized management and helps clinicians deal with the most correct therapy with the fewest adverse events. WES is reported as one of the best routine methods of molecular diagnosis, which is especially useful for complex genetic disorders with different subtypes [18, 19]. It is known that mutations can happen in a specific race and have restricted geographical or ethnical distribution, so the results of this study will help improve gene variant spectrum, diagnostic panels, clinical diagnosis, and patient management not only in this country but also in the region [20]. In MMA genes, a wide variety of mutations was reported; they are significantly varied in presentation or pathological findings among various races. For example, it is reported that the variants c.394 C > T are associated with late-onset MMA as shown in our results [15]. However, Liu et al. reported that among 8 Chinese patients who carried the variant c.394 C > T only two patients presented late-onset MMA [21]. Therefore, it is worth classifying the new variants as accurately as possible. The best potential techniques to evaluate the functionality of novel variants are the methods related to protein expression such as immunohistochemistry (IHC) and expression profiling as well as MS/MS analysis of metabolic profile. The MS/MS-based assay is a non-expensive and simple analytic method [22, 23]. Metabolite data together with molecular, biochemical, and clinical findings can thus be useful for correct interpretation of new variants as pathogenic or non-pathogenic. Therefore, quantification of metabolites in MAA patients could help identify deleterious variants in cases diagnosed with benign or VUS by genetic testing. To note, early identification of MAA patients before being affected by adverse effects such as neurodevelopmental deficiency, and liver and renal failure can improve long-term quality of life, particularly in children; therefore, a combined comprehensive analysis is recommended [24–26]. The main symptoms of MMA include ketosis, acidosis, hypoglycemia, hyperglycemia, hyperammonemia, and neutropenia. The other major complications are developmental delay, disabling movement disorder with choreoathetosis, growth failure, renal failure, pancreatitis, and functional immune impairment [27, 28]. Nevertheless, MMA has a poor prognosis, and without proper treatment, the condition may result in long-term neurodevelopmental impairments. Therefore, early detection and therapy may effectively help the patients [29]. It is known that the concentration of methylmalonic acid in the urine plus plasma homocysteine may contribute to the identification of genetic variants; however, it still has disadvantages in subtype detection [30]. Besides, mutation analysis not only is the gold standard diagnosis method of MMA subtypes but also can help in choosing the right treatment strategy as well as B12 responsiveness [31]. The four patients (P2, P4, P5, P6) in our study showed a progressive course of MMA, characterized by intellectual impairment and developmental delays, with DQ scores of 70 or less, indicating significant intellectual disability. These findings are consistent with previous studies that report developmental delays and cognitive impairments as common in MMA, especially in more severe cases [32]. Despite early diagnosis and treatment, the low DQ scores highlight the long-term neurodevelopmental impact of MMA. Neuroimaging studies, including MRI scans, revealed structural brain abnormalities such as cerebral atrophy and cortical thinning, particularly in the periventricular regions and frontal lobes, which correlate with the patients’ developmental delays [33]. These results suggest that the neurological damage in MMA contributes to cognitive decline and is not solely a result of metabolic disturbances. This underscores the importance of ongoing monitoring and early intervention to prevent further neurological deterioration. The findings also point to the need for further research into neuroprotective treatments, as structural brain changes may influence long-term outcomes in MMA patients. One of the limitations of this study is the relatively small sample size. Although the results provide valuable insights, the limited sample size restricts the generalizability of the findings. A larger cohort would enhance the robustness of the conclusions and allow for broader application of the results. Furthermore, another limitation is the absence of enzyme assays to identify the specific MMA enzymatic subtypes in each patient. For example, assays for deficiencies such as methylmalonyl-CoA epimerase or methylmalonyl-CoA mutase were not conducted, which could have provided more detailed information on the underlying biochemical defects. Future studies with larger sample sizes and enzymatic testing are needed to validate and extend these findings. Conclusions In conclusion, this study involved six patients with Methylmalonic Acidemia (MAA) and identified a novel variant in the MAA-associated genes. Notably, the patient with the novel variant c.290 + 69G > T (p.?) showed no response to vitamin B12 treatment. Our findings suggest that combining Whole Exome Sequencing (WES) and metabolomic methods can be beneficial for diagnosing MAA, particularly in cases where clinical findings are ambiguous. While WES can be costly, it offers significant diagnostic value, especially in complex cases where traditional methods may be less effective. This study also contributes to expanding the mutational and phenotypic spectrum of MAA disorders, helping to refine diagnostic strategies and improve patient care. Acknowledgements The authors hereby extend their gratitude to the patients for their participation in the present study. We appreciate the database registry of Metabolic (no. 1400-7860). Abbreviations Adenosylcobalamin Complete blood count Developmental quotient Immunohistochemistry Liquid chromatography-tandem mass spectrometry Liver function test Methylmalonyl-CoA mutase Methylmalonic academia Next generation sequencing Polymorphism phenotyping v2 Scale-invariant feature transform Whole exome sequencing White blood cell Author contributions Z.B. and B.G. developed the conception of the study, coordinated the clinical study to collect the clinical data, and assessed the obtained clinical findings. Patients were clinically evaluated and recruited with informed consent by B.G., M.H.I., H.M., and S.I.; Z.B. performed the molecular genetic studies, sequence alignments, and annotations of identified sequence alterations. Z.B. and B.G. drafted the manuscript. All authors discussed, read and approved the final manuscript. Funding This study was financially supported by the Shiraz Transplant Research Center (STRC), affiliated with Shiraz University of Medical Sciences, Shiraz, Iran (Grant No.28294). Data availability The data that support the findings of this study are available from Molecular Genetics Laboratory but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of Molecular Genetics Laboratory. Code availability The datasets generated and/or analyzed during the current study are available in the Genbank repository (GRCh37/hg19, https://www.ncbi.nlm.nih.gov/genome/guide/human/) for MMAB: RefSeq NM_052845.4; MMACHC: RefSeq NM_001330540 or NM_015506.2. Declarations Human ethics and consent to participate All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Bioethics Committee of the Medical University of Shiraz, Iran (No. IR.SUMS.REC.1400.912). Informed consent was obtained from legal guardians. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The data that support the findings of this study are available from Molecular Genetics Laboratory but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of Molecular Genetics Laboratory. The datasets generated and/or analyzed during the current study are available in the Genbank repository (GRCh37/hg19, https://www.ncbi.nlm.nih.gov/genome/guide/human/) for MMAB: RefSeq NM_052845.4; MMACHC: RefSeq NM_001330540 or NM_015506.2.